Antibacterial Activity of Eravacycline Against Carbapenem-Resistant Gram-Negative Isolates in China: An in vitro Study.
carbapenem-resistant
drug sensitivity
eravacycline
gram-negative isolates
tigecycline
time-kill curves
Journal
Infection and drug resistance
ISSN: 1178-6973
Titre abrégé: Infect Drug Resist
Pays: New Zealand
ID NLM: 101550216
Informations de publication
Date de publication:
2023
2023
Historique:
received:
13
11
2022
accepted:
23
03
2023
medline:
24
4
2023
pubmed:
24
4
2023
entrez:
24
04
2023
Statut:
epublish
Résumé
Eravacycline is a novel, fully synthetic fluorocycline antibiotic being developed for the treatment of serious infections, with a broad-spectrum antimicrobial activity, including against carbapenem-resistant gram-negative bacteria (CRGNB). However, the in vitro activity of eravacycline against CRGNB has not been well known in China. In this study, we analysed the antibacterial activity of eravacycline against CRGNB isolates in order to provide a theoretical basis for the clinical treatment. A total of 346 isolates of CRGNB were collected from two different tertiary care hospitals in Zhejiang, China. Carbapenem resistance genes of all isolates were detected by polymerase chain reaction. And we analysed the in vitro activity of eravacycline against CRGNB by antimicrobial susceptibility tests. In addition, the time-kill curves were generated to evaluate the antibacterial effect of tigecycline and eravacycline. Four different types of carbapenem-resistant isolates were collected, including 50 Our research indicated that eravacycline had a good antibacterial effect on CRGNB, which could provide a theoretical basis for the clinical treatment of drug-resistant bacterial infections in the future.
Identifiants
pubmed: 37090037
doi: 10.2147/IDR.S396910
pii: 396910
pmc: PMC10120866
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2271-2279Informations de copyright
© 2023 Zou et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest in this work.
Références
Eur J Clin Microbiol Infect Dis. 2019 Oct;38(10):1787-1794
pubmed: 31175478
Nat Microbiol. 2019 Sep;4(9):1457-1464
pubmed: 31235960
Virulence. 2017 May 19;8(4):403-416
pubmed: 27384881
J Antimicrob Chemother. 2015 Mar;70(3):811-7
pubmed: 25344808
Antimicrob Agents Chemother. 2015 May;59(5):2567-71
pubmed: 25691636
Emerg Microbes Infect. 2018 Aug 1;7(1):139
pubmed: 30068997
Microbiol Spectr. 2022 Oct 26;10(5):e0139022
pubmed: 35972286
Antimicrob Agents Chemother. 2013 Oct;57(10):5151-4
pubmed: 23877678
Pharmacotherapy. 2020 Mar;40(3):221-238
pubmed: 31944332
Int J Antimicrob Agents. 2020 Dec;56(6):106178
pubmed: 32980393
Drugs. 2019 Feb;79(3):315-324
pubmed: 30783960
Int J Antimicrob Agents. 2020 Dec;56(6):106215
pubmed: 33122095
Drugs Today (Barc). 2018 Apr;54(4):245-254
pubmed: 29869646
Eur J Clin Microbiol Infect Dis. 2022 Jul;41(7):1003-1022
pubmed: 33403565
Int J Antimicrob Agents. 2006 Apr;27(4):351-3
pubmed: 16564159
Antimicrob Agents Chemother. 2016 Jul 22;60(8):5001-5
pubmed: 27353265
Clin Infect Dis. 2018 Nov 13;67(suppl_2):S196-S205
pubmed: 30423057
Lancet Infect Dis. 2017 Jul;17(7):726-734
pubmed: 28442293
BMJ Open. 2021 Dec 14;11(12):e054971
pubmed: 34907071
Antimicrob Agents Chemother. 2015 Mar;59(3):1802-5
pubmed: 25534744
Int J Antimicrob Agents. 2021 Sep;58(3):106377
pubmed: 34166777
Diagn Microbiol Infect Dis. 2011 May;70(1):119-23
pubmed: 21398074
Front Cell Infect Microbiol. 2017 May 24;7:209
pubmed: 28596943
Front Microbiol. 2020 May 25;11:916
pubmed: 32523563
Infect Genet Evol. 2020 Jun;80:104185
pubmed: 31923725
Antimicrob Agents Chemother. 2019 Apr 25;63(5):
pubmed: 30858207
Expert Rev Anti Infect Ther. 2018 Feb;16(2):89-110
pubmed: 29310479
Drugs. 2016 Apr;76(5):567-88
pubmed: 26863149
Arch Razi Inst. 2021 Nov 30;76(5):1297-1305
pubmed: 35355735
Open Forum Infect Dis. 2018 Jun 28;5(7):ofy150
pubmed: 30046639
Int J Antimicrob Agents. 2018 Jan;51(1):62-64
pubmed: 28705668
Diagn Microbiol Infect Dis. 2018 May;91(1):55-62
pubmed: 29338931
Philos Trans R Soc Lond B Biol Sci. 1980 May 16;289(1036):321-31
pubmed: 6109327
Front Cell Infect Microbiol. 2022 May 12;12:902774
pubmed: 35646740
Antimicrob Agents Chemother. 2018 Jan 25;62(2):
pubmed: 29203488
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S565-S575
pubmed: 31724043